Ghbeis Muhammad Bakr, Pane Caroline, Beroukhim Rebecca, Feins Eric, Del Nido Pedro J, Sleeper Lynn A, Emani Sitaram E, Kheir John N
Department of Cardiology, Boston Children's Hospital, Boston, Massachusetts, USA.
Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
JACC Adv. 2024 Dec 17;4(1):101429. doi: 10.1016/j.jacadv.2024.101429. eCollection 2025 Jan.
The Fontan operation is associated with chronic venous hypertension, liver and renal disease, and several other sequelae. The alterative surgical approach, when feasible, a biventricular conversion (BiV), may diminish some of these long-term risks.
The aim of this study was to compare long-term outcomes of patients undergoing BiV with those undergoing a destination Fontan operation.
We identified all patients with univentricular physiology cared for at Boston Children's Hospital between 2007 and 2022 and divided them into those who received BiV or Fontan operations. Outcomes included 10-year incidences of modified major adverse cardiovascular events (MACE), liver dysfunction, renal dysfunction, and transplant-free survival. Outcomes in the 2 groups were compared using propensity matching.
A total of 927 patients were evaluated, 341 BiV and 586 Fontan. Following propensity matching, 258 patients from each group were compared. There were no differences between groups in estimated 10-year freedom from MACE ( = 0.70), transplant-free survival ( = 0.70), or freedom from renal disease ( = 0.60). However, estimated 10-year freedom from liver disease was greater in BiV patients (82% BiV vs 71% Fontan, = 0.02). Incidence rate per 100 person-years follow-up of surgical interventions and readmissions was higher among BiV patients (10.11 vs 1.85, < 0.001 and 13.09 vs 9.6, = 0.002), while catheter-based interventions were higher among Fontan patients (8.41 vs 4.63, < 0.001).
Among a contemporary cohort of patients with single ventricle anatomy, BiV provide comparable long-term survival and lower risk of liver disease when compared to patients who have undergoing Fontan operations.
Fontan手术与慢性静脉高压、肝脏和肾脏疾病以及其他几种后遗症相关。另一种手术方法,在可行时进行双心室转换(BiV),可能会降低其中一些长期风险。
本研究的目的是比较接受BiV手术的患者与接受最终Fontan手术的患者的长期结局。
我们确定了2007年至2022年期间在波士顿儿童医院接受治疗的所有单心室生理患者,并将他们分为接受BiV或Fontan手术的患者。结局包括改良主要不良心血管事件(MACE)、肝功能障碍、肾功能障碍和无移植生存的10年发生率。使用倾向匹配法比较两组的结局。
共评估了927例患者,341例接受BiV手术,586例接受Fontan手术。倾向匹配后,比较了每组的258例患者。两组在估计的10年无MACE生存率(P = 0.70)、无移植生存(P = 0.70)或无肾脏疾病生存率(P = 0.60)方面没有差异。然而,BiV患者的估计10年无肝病生存率更高(BiV组为82%,Fontan组为71%,P = 0.02)。BiV患者每100人年随访的手术干预和再入院发生率更高(分别为10.11对1.85,P < 0.001和13.09对9.6,P = 0.002),而基于导管的干预在Fontan患者中更高(8.41对4.63,P < 0.001)。
在当代单心室解剖结构的患者队列中,与接受Fontan手术的患者相比,BiV提供了相当的长期生存率和更低的肝病风险。